Study details
Enrolling now
Naltrexone in AUD Reward Drinkers
University of Pennsylvania
NCT IDNCT05028062ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
60
Study length
about 5.8 years
Ages
18–65
Locations
1 site in PA
About this study
This trial is testing whether XR-NTX, a long-acting injectable naltrexone, helps reward drinkers with Alcohol Use Disorder reduce heavy drinking compared to a placebo. Participants will receive monthly injections of either XR-NTX or a matching placebo along with medical management sessions. It lasts for 2125 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Participate in Medical Management
- 2.Receive Placebo intramuscular injection
- 3.Receive XR-NTX 380 mg, intramuscular injection
PhasePhase 4
Routeinjection
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
injection
Body systems
Psychiatry / Mental Health